The short answer
Alpha-MSH is thirteen residues. Semax retains positions 4 to 7, MT-2 is built around a core corresponding to positions 6 to 9, and KPV is positions 11 to 13 exactly. Three separate product categories on this site are fragments of one sequence.
Key facts
- Parent
- alpha-MSH, 13 residues, 1,664.9 Da
- Semax retains
- Positions 4-7, Met-Glu-His-Phe
- Semax replaces
- Positions 8-10 with Pro-Gly-Pro
- MT-2 core
- His-D-Phe-Arg-Trp, positions 6-9
- KPV
- Lys-Pro-Val, positions 11-13
- Overlap
- Semax and MT-2 share His-Phe (6-7)
- KPV
- Adjacent and non-overlapping
The parent sequence
Alpha-MSH runs Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val, acetylated at the front and amidated at the end. Numbering those positions one to thirteen is what makes the fragment literature legible. Every compound discussed here is described by which of those positions it keeps.
Where Semax sits
Semax is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues are positions 4 to 7 of the parent. What follows is not the parent's positions 8 to 10 (Arg-Trp-Gly) but Pro-Gly-Pro substituted in their place. So Semax keeps the front of the shared region and discards the part that follows it.
Research material referenced
Semax 10mg, third-party HPLC tested
Where MT-2 sits
MT-2 is a cyclic heptapeptide whose core reads His-D-Phe-Arg-Trp, corresponding to positions 6 to 9, with norleucine standing in for the methionine position and D-phenylalanine replacing the L form. Those four residues are the recognised melanocortin receptor-binding core, which is why a compound built to engage those receptors is built around them.
Where KPV sits
KPV is Lys-Pro-Val, positions 11, 12 and 13, the C-terminal end of the parent, taken unmodified. It is the only one of the three that is an exact excerpt rather than an analogue.
What the map shows
Semax and MT-2 overlap at His-Phe, positions 6 and 7. KPV lies beyond both, adjacent and non-overlapping. The three compounds together cover most of the parent's second half, carved into pieces by three different research programmes pursuing three different questions, cognition, pigmentation and inflammation.
Why the pieces behave so differently
Because what each retains determines what it can do. MT-2 keeps the receptor-binding core and is built to engage melanocortin receptors. KPV keeps the C-terminal tail associated with anti-inflammatory activity and deliberately discards the receptor core. Semax keeps the front of the region and replaces what follows with a stability motif. Same parent, three different design intentions, three different molecules.
The regulatory position across all three
None of Semax, MT-2 or KPV holds a marketing authorisation from the MHRA, EMA or FDA. All are supplied here for laboratory research only, and no claim is made about any of them in relation to any condition in any person.
Quick reference
| Compound | alpha-MSH positions | Relationship |
|---|---|---|
| Semax | 4-7 retained | Analogue (8-10 replaced by Pro-Gly-Pro) |
| MT-2 | 6-9 as core | Analogue (cyclised, D-Phe, Nle) |
| KPV | 11-13 | Exact excerpt |
Frequently asked questions
Do any of them overlap?
Semax and MT-2 share His-Phe at positions 6 and 7. KPV, at positions 11 to 13, is adjacent and does not overlap either.
Why do they behave so differently?
Because what each retains determines what it can do, MT-2 keeps the receptor-binding core, KPV keeps the C-terminal tail and discards that core.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedDores RM: Ann N Y Acad Sci 2011 (PMID 21388402)pubmed.ncbi.nlm.nih.gov
- PubMedSandman CA et al., MSH/ACTH 4-10. J Clin Endocrinol Metab 1977 (PMID 192754)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · alpha-MSH (CID 16133793)pubchem.ncbi.nlm.nih.gov
- PubChemPubChem · Melanotan II (CID 92432)pubchem.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Semax (ACTH Fragment Peptide) articles
- Where This Line of Research StartedBefore Semax existed, ACTH(4-10) itself was studied for effects on memory and attention. Two 1970s papers set the question that Semax inherited.
- What the Melanocortin Neuroprotection Literature ReportsCatania 2008 reviewed neuroprotective actions of melanocortins. Giuliani 2006 examined MC4R-stimulating melanocortins in cerebral ischaemia models.
- A Mechanism Layer Below Gene ExpressionKolbaev 2025 examined Semax and calcium dynamics in rat brain neurons - a faster timescale than the neurotrophin expression work.
- What the Animal Behavioural Work ReportsGlazova 2021 examined Semax against alterations following early-life fluvoxamine exposure in rats. Why the model design is the interesting part.
- What a Fragment Keeps Decides What It DoesThree fragments of alpha-MSH pursue pigmentation, inflammation and cognition. The difference is not the parent - it is which residues each retained.